تاثیر پپتید آنتاگونیست VEGFB بر میزان بیان miR-210 در سرطان پستان مدل موشی

نویسندگان

1 دانشکده علوم زیستی، واحد تنکابن، دانشگاه آزاد اسلامی، تنکابن، ایران

2 گروه زیست‌شناسی دانشکده علوم پایه، دانشگاه گیلان، رشت، ایران

3 گروه زیست‌شناسی دانشکده علوم پایه، دانشگاه گیلان، رشت، ایران؛ مرکز تحقیقات بیوشیمی و بیوفیزیک دانشگاه تهران، تهران، ایران

چکیده
سرطان پستان چهارمین سرطان شایع در سراسر جهان است و زمانی اتفاق می‌افتد که سلول‌های پستان به­ طور غیر قابل کنترلی تقسیم شوند و تومور تشکیل بدهند. رگ­زایی یکی از عوامل مهم در رشد و حفظ هموستاز سلول در شرایط طبیعی و پاتولوژیک است و VEGFs از مهم‌ترین عوامل موثر در رگ­زایی هستند. miR-210 از طریق ارتباط با VEGF در رگ­زایی نقش مهمی ایفا می­ کند. در این مقاله تغییرات بیان miR-210 در پاسخ به پپتید ضد رگ­زایی آنتاگونیست VEGFB (موسوم به VEGB1) در موش ­های ماده نژاد BALB/c، دارای تومور پستان القاء شده با رده سلولی 4T1 مطالعهشد. گروه تحت درمان مقادیر 1mg.kg-1 و 10mg.kg-1 از پپتید و گروه کنترل، PBS را به طریق درون صفاقی (ip) به مدت دو هفته دریافت کردند. چهارده روز پس از تیمار، بافت پستانی از هر دو گروه حیوانات جداسازی و میزان بیان miR-210 بررسی شد. تحلیل آماری نتایج با استفاده از One Way ANOVA بیانگر وجود اختلاف معنا­دار در میزان بیان miR-210 میان گروه‌های تیمارشده با مقادیر مختلف VEGB1 بود. همچنین بیان این ژن میان گروه­های تیمار شده با پپتید با نمونه­ های شاهد تفاوت معنی­ دار داشت ( p<0.05 ). در موش­ های تیمار شده با یک میلی­ گرم بر کیلوگرم از VEGB1 میزان بیان miR-210، 42 درصد کاهش بیان داشت، اما کاهش 90 درصدی بیان miR-210 در موش­ های تیمار شده با 10میلی­گرم بر کیلوگرم VEGB1 مشاهده گردید که نشان­ دهنده عملکرد مهاری پپتید آنتاگونیست VEGB1 در مقادیر مختلف است.





کلیدواژه‌ها


عنوان مقاله English

The effect of a VEGFB antagonist peptide on the expression level of miR-210 in a mouse model of breast cancer

نویسندگان English

Fatemeh Kaboudan 1
Soheila Talesh Sasani 2
Seyed Mohsen Asghari 3
1 Faculty of Biological Science, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran
2 Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran
3 Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran; Iran Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran
چکیده English

Breast cancer is the fourth common cancer worldwide and occurs when breast cells begin to uncontrolled division and tumor formation. Angiogenesis is one of the essential factors in cell growth and maintenance of homeostasis in the natural and pathological conditions, while VEGFs are the most critical factors in angiogenesis. MiR-210 plays an important role in the angiogenesis via association with VEGF. Here, the miR-210 expression changes in response to a VEGFB antagonist peptide, called VEGB1, was studied in female BALB/c mice bearing 4T1 cell line induced breast tumor. The treated group received 1mg.kg-1 and 10mg.kg-1 of the peptide and the control group received PBS intraperitoneally during two weeks. Both of the animal groups underwent a resection of breast tissue 14 days after treatment and miR-210 expression level was investigated. Statistical analysis by On-way ANOVA showed that the expression level of miR-210 gene had significant differences among the groups treated with various doses of VEGB1. Also, the gene expression was significantly different between peptide-treated groups and control samples (p<0.05). MiR-210 expression level had 42% reduction in mice treated with 1mg.kg-1 of VEGB1, while 90% was seen in mice treated with 10mg.kg-1 of VEGB1 showing the inhibitory function of VEGB1 antagonist peptide at different doses.

کلیدواژه‌ها English

Angiogenesis
regulation of gene expression
Hypoxia
metastasis
Statistical analysis
Aliati, M.A., Ishikawa, M., Masuda, H., Simon, D.I., Jian, M.K., Asahra, T. & Costa, M.A. 2012. Upregulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. Journal of Cellular and Molecular Medicine 16: 2413- 2421.
Almeida, M. I., Reis, R. M. & Calin, G. A. 2011. MicroRNA history: discovery, recent applications, and next frontiers. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 717: 1-8.
Assareh, E., Mehrnejad, F., Mansouri, K., Esmaeili Rastaghi, A.R., Naderi-Manesh, H. & Asghari, S.M. 2019. A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth. Biochemical Journal 476: 645-663.
Baharara, J., Zafar-Balanejad, S., Nejad-Shahrokhabadi, K. & Hesami, Z. 2012. The effects of different doses of atorvastatin on angiogenesis of chorioallantoic membrane of chick embryo. Journal of Shahrekord University of Medical Sciences 14: 82-89.
Baharara, J., Ramezani, T., Saghiri, N. & Salek, F. 2019. Investigating the apoptotic effects of silver nanoparticles coated with Achillea biebersteinii extract on A2780 ovarian cancer cells. Nova Biologica Reperta 6: 140-147. (In Persian).
Bauer, S.M., Bauer, R.J. & Velazquez, O.C. 2005. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vascular and Endovascular Surgery 39: 293-306.
Bavelloni, A., Ramazzotti, G., Poli, A., Piazzi, M., Focaccia, E., Balalock, W. & Faenza, I. 2017. MiRNA-210: A Current Overview. Anticancer Research 37: 6511-6521.
Bianchi, N., Zuccato, C., Lampronti, I., Borgatti, M. & Gambari, R. 2009. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Reports 42: 493-499.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L.A. & Jemal, A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 68: 394-424.
Carmeliet, P. & Jain, R.K. 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
Carramolino, L., Fuentes, J., García-Andrés, C., Azcoitia, V., Riethmacher, D. & Torres, M. 2010.
Platelets play an essential role in separating the blood and lymphatic vasculatures during embryonic angiogenesis. Circulation Research 106: 1197-201
Desantis, C., Siegel, R., Bandi, P. & Jemal, A. 2011. Breast cancer statistics, 2011. CA: a Cancer Journal for Clinicians 61: 408-418.
Egginton, S. 2009. Invited review: activity-induced angiogenesis. Pflügers Archiv-European Journal of Physiology 457: 963-977.


Folkman, J. 1990. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82: 4-7.
Folkman, J., 1971. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285: 1182-1186.
Fukasawa, M., Matsushita, A. & Korc, M. 2007. Neuropilin-1 interacts with integrin β1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biology & Therapy 6: 1184-1191.
Kamat, A., Rajoria, S., George, A., Suriano, R., Shanmugam, A., Megwalu, U., Prakash, P.B., Tiwari, R. & Schantz, S. 2011. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Archives of Otolaryngology–Head & Neck Surgery 137: 1146-1153.
Kerbel, R. S. 2000. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515.
Kolahdoozan, S., Sadjadi, A., Radmard, A.R. & Khademi, H. 2010. Five common cancers in Iran. Archives of Iranian Medicine 13: 143-146.
Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. & Ferrara, N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
Meimandi, K. & Yaghoobi, M.M. 2019. The effect of aqueous and ethanolic extracts of Sedum album L. on human stomach and breast carcinoma cell lines in vitro. Nova Biologica Reperta 6: 10-19. (In Persian).
Noroozi, A., Jomand, T. & Tahmasebi, R. 2011. Determinants of breast self-examination performance among Iranian women: an application of the health belief model. Journal of Cancer Education 26: 365-374.
Odorisio, T., Cianfarani, F., Failla, C.M. & Zambruno, G. 2006. The placenta growth factor in skin angiogenesis. Journal of Dermatological Science 41: 11-19.
Prewett, M., Huber, J., Li, Y., Santiago, A., O’Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L. & Bohlen, P. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Research 59: 5209-5218.
Ramezani., S., Talesh Sasani, S., Fakor, F. & Alizadehsefat, S. 2020. Relationship of the expression of circulating hsa-miR-125a-3p and hsa-miR125b with breast cancer. British Journal of Biomedical Science 77: 41-43.
Sadremomtaz, A., Kobarfard, F., Mansouri, K., Mirzanejad, L. & Asghari, S.M. 2018. Suppression Of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2. Journal of Receptors and Signal Transduction 38: 432-441.
Sempere, L.F. & Kauppinen, S. 2009. Translational implications of microRNAs in clinical diagnostics and therapeutics. Handbook of Cell Signaling (2nd ed.). Elsevier.
Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H. & Sato, M.J.O. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519-524.
Smith, R.A., Andrews, K. S., Brooks, D., Fedewa, S.A., Manassaram‐Baptiste, D., Saslow, D., Brawley, O.W. & Wender, R.C. 2017. Cancer screening in the United States: a review of current American Cancer Society guidelines and current issues in cancer screening. CA: a Cancer Journal for Clinicians 67: 100-121.
Stewart, B. & Wild, C.P. 2014. World cancer repot. World Health Organization, Geneva.
Wang, Z., Deng, M., Liu, Z. & Wu, S. 2017. Hypoxia-induced miR-210 promoter demethylation enhances proliferation, autophagy and angiogenesis of schwannoma cells. Oncology Reports 37: 3010-3018.
Zeng, L., He, X., Wang, Y., Tang, Y., Zheng, C., Cai1, H., Liu, J., Wang, Y., Fu, Y. & Yang, G-Y. 2014. MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse Brain. Gene Therapy 21: 37-43

  • تاریخ دریافت 18 خرداد 1405
  • تاریخ انتشار 18 خرداد 1405